SCHEDULE 13D/A: Acorn Bioventures Increases Stake in OnKure Therapeutics to Over 22% Following Recent Share Purchase

Acorn Bioventures and its affiliates have significantly increased their beneficial ownership in OnKure Therapeutics, Inc. to 22.1% through recent share acquisitions and a prior merger.

Summary

• Acorn Bioventures, L.P., Acorn Bioventures 2, L.P., and their affiliates, including Anders Hove, collectively hold a significant beneficial ownership in OnKure Therapeutics, Inc.
• Anders Hove, as the manager of the general partners, beneficially owns 2,839,674 shares, representing 22.1% of the Issuer's common stock.
• Acorn Bioventures, L.P. beneficially owns 1,709,944 shares, which is 13.3% of the class.
• Acorn Bioventures 2, L.P. beneficially owns 1,129,730 shares, representing 8.8% of the class.
• These percentages are based on 12,823,872 shares of Common Stock outstanding as of May 5, 2025.
• The shares were acquired solely for investment purposes, with no present plans for changes in the Issuer's business, policies, management, structure, or capitalization.
• On October 4, 2024, the Issuer (formerly Reneo Pharmaceuticals, Inc.) completed a merger with OnKure, Inc. (Legacy OnKure), which resulted in Acorn receiving 1,439,674 shares of the Issuer's Common Stock.
• On May 15, 2025, Acorn and Acorn 2 acquired an additional 270,270 and 1,129,730 shares, respectively, in an open market block purchase.
• The May 2025 shares were acquired at a price of $1.85 per share, for an aggregate consideration of $2,590,000, using funds from working capital.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of beneficial ownership and investment intent. The substantial and increasing stake by a specialized biotech investor (Acorn Bioventures) can be interpreted as a positive signal of confidence in OnKure Therapeutics. However, the explicit reservation of rights by the Reporting Persons to pursue various strategic actions, even if not currently planned, introduces a degree of potential future uncertainty, preventing a higher sentiment score. It is not a negative filing, but also not overwhelmingly positive in terms of company performance or immediate operational outlook.

Positives

• The significant and increasing investment by Acorn Bioventures, a specialized biotechnology investor, indicates a strong vote of confidence in OnKure Therapeutics, Inc.
• The recent open market block purchase of additional shares at $1.85 per share demonstrates continued commitment and belief in the Issuer's value.

Risks

• The Reporting Persons reserve the right to acquire or dispose of additional securities of the Issuer, which could lead to increased stock price volatility.
• While no present plans exist, the Reporting Persons may consider various alternative courses of action, including extraordinary corporate transactions (such as a merger, reorganization, or liquidation), sale or transfer of material assets, changes in the board of directors or management, material changes in capitalization or dividend policy, or other changes in the Issuer's business or corporate structure, which could introduce uncertainty for other shareholders and potentially impact the company's strategic direction.

Future Outlook

The Reporting Persons state that their acquisition of shares is solely for investment purposes and they currently have no plans or proposals to change the Issuer's business, policies, management, structure, or capitalization. However, they explicitly reserve the right to acquire or dispose of additional securities and may consider various alternative courses of action in the future, including extraordinary corporate transactions, asset sales, changes in management or the board, or alterations to the Issuer's capitalization or corporate structure, depending on market conditions and other factors.

Management Comments

• "The shares of Common Stock reported herein were acquired solely for investment purposes."
• "None of the Reporting Persons have any present plans or proposals that relate to or would result in any change in the business, policies, management, structure or capitalization of the Issuer."
• "The Reporting Persons reserve the right to acquire, or dispose of, additional securities of the Issuer in the ordinary course of their business, to the extent deemed advisable in light of their general investment and trading policies, market conditions or other factors."

Industry Context

This filing indicates a significant and growing investment by a specialized biotechnology investor in OnKure Therapeutics, a company that recently completed a merger. Such substantial ownership stakes by institutional investors are a common feature in the biotechnology sector, where companies often rely on external funding and strategic partnerships to advance their drug development pipelines and achieve commercialization. The merger itself is a typical strategic maneuver in biotech, aimed at combining assets, technologies, or achieving greater scale.

Corporate Governance

Stakeholder Impact

• Shareholders: The increased concentration of ownership by a significant institutional investor could lead to more active engagement or influence on corporate strategy. The potential for future strategic actions by the Reporting Persons, even if not currently planned, could introduce uncertainty or opportunities for shareholder value.
• Management/Board: The presence of an affiliate of the Reporting Persons on the board, coupled with the stated potential for the Reporting Persons to seek changes in management or board composition, could influence the company's strategic direction and operational decisions.

Next Steps

• The Reporting Persons may acquire or dispose of additional securities of the Issuer in the ordinary course of their business.
• The Reporting Persons may engage in discussions from time to time with other stockholders of the Issuer regarding the acquisition of shares.
• The Reporting Persons may consider various alternative courses of action with respect to their investment, including extraordinary corporate transactions (e.g., merger, reorganization, liquidation), sale or transfer of material assets, changes in the board of directors or management, material changes in capitalization or dividend policy, or other changes in the Issuer's business or corporate structure.

Key Dates

Keywords

OnKure Therapeutics, Acorn Bioventures, Schedule 13D, Beneficial Ownership, Biotechnology, SEC Filing, Investment, Common Stock, Merger, Share Acquisition, Reneo Pharmaceuticals